5-甲基-4,5,6,7-四氢-苯并[B]噻吩-2-羧酸 | 588698-05-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 5-甲基-4,5,6,7-四氢-苯并[B]噻吩-2-羧酸
• 中文别名: 5-甲基-4,5,6,7-四氢-1-苯并噻吩-2-羧酸；5-甲基-4,5,6,7-四氢苯并噻吩-2-羧酸
• 英文名称: 5-Methyl-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxylic acid
• CAS: 588698-05-9
• 化学式: C₁₀H₁₂O₂S
• mdl: MFCD03944879
• 分子量: 196.27
• InChiKey: AKQCTDMGIZKFRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2934999090

文献信息

• Certain substituted amides, method of making, and method of use thereof
  申请人：Brittelli R. David

  公开号：US20060229337A1

  公开（公告）日：2006-10-12

  At least one chemical entity chosen from compounds of Formula 2 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein. Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

  本文描述了至少选择自公式2化合物和药学上可接受的盐、溶剂化合物、螯合物、非共价复合物、前药和其混合物中的至少一种化学实体。本文还描述了包括本发明中至少一种化学实体以及至少一种药学上可接受的载体、佐剂和赋形剂在内的制药组合物。本文还描述了治疗对Btk活性和/或B细胞活性抑制有反应的某些疾病的患者的方法。本文还描述了用于确定样品中Btk存在的方法。
• CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
  申请人：Currie Kevin S.

  公开号：US20080125417A1

  公开（公告）日：2008-05-29

  At least one chemical entity chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof, is described herein. Pharmaceutical compositions comprising at least one chemical entity of Formula 1, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

  本文描述了至少选择自公式1化合物及其药学上可接受的盐、溶剂化合物、螯合物、非共价复合物、前药和混合物中的至少一种化学实体。本文还描述了包括公式1化学实体和至少一种药学上可接受的载体、佐剂和辅料在内的制药组合物。本文还描述了治疗对Btk活性和/或B细胞活性抑制敏感的某些疾病的患者的方法。本文还描述了检测样本中Btk存在的方法。
• Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
  申请人：Whitney James A.

  公开号：US20100160292A1

  公开（公告）日：2010-06-24

  Methods of inhibiting BTK activity by inhibiting phosphorylation of Y551 of BTK, methods of treating patients by inhibiting BTK activity by inhibiting phosphorylation of Y551 of BTK, chemical entities that bind to BTK and inhibited complexes are provided.

  提供通过抑制BTK Y551的磷酸化来抑制BTK活性的方法，提供通过抑制BTK Y551的磷酸化来治疗患者的方法，提供结合BTK并抑制复合物的化学实体。
• CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF
  申请人：CGI Pharmaceuticals, Inc.

  公开号：EP1863766A2

  公开（公告）日：2007-12-12
• PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS
  申请人：CGI Pharmaceuticals, Inc.

  公开号：EP2069314A1

  公开（公告）日：2009-06-17